Opinion: Obesity drugs may silence the ‘drug noise’ behind all addiction
A BMJ observational analysis of more than 600,000 people found GLP‑1 receptor agonists were associated with 50% fewer substance-related deaths, 39% fewer overdoses, and 26% fewer drug-related hospitalizations, and with lower incidence of new substance use disorders across alcohol, opioids, cocaine, cannabis, and nicotine. Animal studies and international registry data showed reduced consumption and craving, suggesting a shared brain-based reward mechanism tied to GLP‑1 signaling; authors call for randomized trials that measure overdose, hospitalization, and mortality and note unanswered questions about dependence on weight loss, long-term neuroadaptation, and relapse after discontinuation.
Why it mattersBMJ analysis of over 600,000 people found GLP‑1 drugs linked to 50% fewer substance-related deaths.